MFE-23-CD3z T cell therapy (Cancer Research Technology)

N/A

Report date: 2022/02/17 13:33:34

Base Information

Drug NameMFE-23-CD3z T cell therapy (Cancer Research Technology)

Drug Alias NameMFE-23-CD3z T cell therapy (cancer)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonists

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCancer Research Technology

China Registration ClassN/A

Develop Information

Active CompaniesCancer Research Technology

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A